CLPH-211, Perioperative Hemostatic Agent, the lead Freeze-dried Platelet-derived hemostatic (FPH) technology product. The Denmark Phase 2 clinical trials completed enrollment in March 2024 with top line data available in Q2 2024.  With 70 human exposures, CLPH-211 has strong clinical safety data with significant, additional pre-clinical safety data. The product has 3+ year room temperature stability and simple rehydration with sterile water in minutes. CLPH-211 benefits from Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense (Army) support due to the mission fit.

Cryopreserved Platelets (CLPH-511), the furthest advanced product in the portfolio, utilizes cryopreservation of platelets (CPP).  Put on the MPAC list in October 2023, this critical program is in a Phase 2/3 clinical trial. Addressing liquid stored platelet (LSP) availability challenges for rural and field hospitals. Targeting BLA in 2027, CLPH-511’s development is substantively funded by the Department of Defense. CPP is comprised of frozen platelets stabilized with a cryoprotectant, DMSO (dimethyl sulfoxide). CPP can be cryopreserved for up to 5 years, unlike standard platelets which can only be stored for 5 to 7 days.